Navigation Links
Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
Date:9/6/2011

reatment option for HER2-positive patients with advanced breast cancer in a pivotal phase III clinical trial called LUX-Breast 1. Studies 1200.89 and LUX-Breast 1 include biomarker testing of tumor tissues.

Breast cancer is the second-leading cause of cancer death in women after lung cancer.  An estimated 39,520 American women are expected to die from breast cancer in 2011.(1)  It is thought that women overexpress the HER2 protein in approximately 30 percent of advanced breast cancer cases.(2)  

"There is a need for more treatment options for patients with aggressive HER2-positive breast cancer. These studies are important because they will help us to further explore the potential of afatinib in this difficult-to-treat group of patients," said Andree Amelsberg, M.D., Executive Director, Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. 

About the Afatinib Clinical Program

The LUX trial program is a comprehensive and robust program that comprises more than 10 trials conducted across the globe, investigating afatinib for potential approval for a variety of solid tumor types, including NSCLC, breast and head and neck cancer.  In breast cancer specifically, the following trials are underway:

Afatinib in HER2-Positive Metastatic Breast Cancer After One Prior Trastuzumab Treatment (LUX-Breast 1)

LUX-Breast 1 is a global, open-label, randomized study in nearly 800 HER2-positive patients with advanced breast cancer after prior treatment with trastuzumab. The primary endpoint of the study evaluates whether treatment with afatinib can extend the time until cancer progresses (i.e., progression-free survival or PFS) as compared to continuing treatment with trastuzumab, when both are added to the standard chemotherapy treatment vinorelbine. Overall survival and safety are among the secondary endpoints that will be assessed in the trial.  For more information, please visit <
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015   GenSpera, Inc. ... Patent and Trademark Office has issued U.S. Patent ... portfolio claiming numerous compositions for the company,s prodrugs ... (PSA).  GenSpera is developing a ... a powerful cytotoxin isolated from the poisonous plant, ...
(Date:4/28/2015)... , April 28, 2015  Unfors RaySafe, the ... new radiation Survey sensor aimed at expanding the RaySafe ... X2 Survey sensor is the easiest and fastest solution ... It is the latest addition to the continually expanding ... to perform leakage and scatter measurements in diagnostic X-ray ...
(Date:4/28/2015)... 28, 2015 /CNW/ - The group representing the living victims ... left a two-hour meeting with Health Canada officials in ... Health Canada announced a $180 million support package for ... weeks after the Health Canada announcement and five months ... the victims, the group representing Canada,s ...
Breaking Medicine Technology:GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen 2Unfors RaySafe, a Fluke Biomedical company, unveils a new Survey sensor for the RaySafe X2 2Thalidomide Victims Gravely Concerned by Health Canada's Silence 2
... July 28, 2011 /PRNewswire/ -- ... and stabilization, and the US Army Medical Research Institute ... a Cooperative Research and Development Agreement (CRADA) to develop ... The two organizations will collaborate on the ...
... Inc. (NYSE: HRC ), announced financial results for ... its outlook for 2011. Adjusted earnings per diluted share increased ... earnings per diluted share in the fiscal third quarter decreased ... the prior year, and net income declined to $2 million ...
Cached Medicine Technology:Biomatrica and USAMRIID Sign a CRADA for the Development of New Technologies Applicable for Ambient Stabilization of Clinical and Biological Samples 2Biomatrica and USAMRIID Sign a CRADA for the Development of New Technologies Applicable for Ambient Stabilization of Clinical and Biological Samples 3Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 2Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 3Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 4Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 5Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 6Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 7Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 8Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 9
(Date:4/28/2015)... 28, 2015 Foot and Ankle ... Stephen D. Palmer ( Annapolis and Clarksville Divisions ... podiatry at the Maryland Podiatric Medical Association meeting on ... State University in 1992 with a Bachelor of Arts ... participated in intercollegiate soccer, track and cross-country. He then ...
(Date:4/28/2015)... 28, 2015 Foundations Recovery Network (FRN), ... announce the rebranding of its Memphis based residential treatment ... Center will now be known as The Oaks at ... a stand of beautiful old Oak trees long regarded ... may be new, the commitment and dedication to helping ...
(Date:4/27/2015)... Medical Device Design Control , Implementing ... Enterprises**, June 16-17, 2015 – Chicago, IL , ... a facility today, would the design control system pass ... "maybe" or "no" … then very likely there is ... solution. , Take this important step. Enroll TODAY ...
(Date:4/27/2015)... NY (PRWEB) April 28, 2015 ... new white paper called “Website Anatomy 101.” ... paper discusses the necessary design elements for a ... emphasis on responsive design, user experience, search results ... the impact of a well-designed website on patient ...
(Date:4/27/2015)... 2015 A new type of festival is ... Science on Tap at the Science Museum of Virginia not ... adds science hops for a bold, new flavor. , The ... serves up the science behind these frothy beverages. Guests uncover ... look at the ingredients that go into beer with Original ...
Breaking Medicine News(10 mins):Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2Health News:Foundations Recovery Network Rebrands LaPaloma Treatment Center as The Oaks at LaPaloma 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Science on Tap at the Science Museum of Virginia 2
... aid stop the spread of cancer cells. Researchers at the University of ... related to the well-known antibiotic tetracycline. In a series of experiments, they ... tumour less likely to spread throughout the body. ... ,COL-3 appears to ...
... who are obese in middle age have premature thickening of ... arteries// in the neck as a useful marker for the ... linings of the carotid arteries are thickened, then it's more ... ,In a new study, doctors in Texas looked at carotid ...
... to a new study it is observed ... newly diagnosed multiple myeloma patients when combined with ... Clinic in Rochester, Minn.// gave 60 newly diagnosed ... synthetic steroid dexamethasone. Results show 55 percent of ...
... to two new studies, reveal people with GERD, ... more likely than others without these conditions to ... quality.// Researchers from Pennsylvania State University selected more ... for sleep-related breathing disorders, to participate in the ...
... aged 40 or over has a lifetime risk of heart ... have high blood pressure. Heart failure is an increasing problem, ... the heart which makes it hard to pump blood around ... condition is very disabling. ,Researchers for the Framingham ...
... researchers suggest that the presence of proteins linked to ... with high blood pressure. Although we know that high ... still the case that not everyone with hypertension actually ... that inflammation could be the key to understanding this ...
Cached Medicine News:
Vial with 100 Urine Reagent Test Strips, tests for glucose, protein, pH, blood, ketone, bilirubin, nitrite, urobilinogen, specific gravity. FOR LABORATORY USE BY QUALIFIED TECHNICIANS....
... Paradigm II utilizes powerful ... modules that provide complete flexibility for you to ... Quality system, while providing transparent accountability to all ... or Intranet . Paradigm II uses ...
... MasterControl architecture is the power behind ... provides all the essential building blocks ... management system to boost operational efficiency, ... with regulatory and quality standards. Click ...
... easy to operate and maintain. The units ... flexible snap-seal pockets which minimize the potential ... the water. Offered in two-, four-, and ... bags of various sizes. ThermoLine Thawing Systems ...
Medicine Products: